Human Metabolome Project

Human Metabolome Project
Name	Human Metabolome Project
Founded	2004
Founders	David S. Wishart
Location	Edmonton, Alberta

Human Metabolome Project The Human Metabolome Project is a large-scale bioinformatics and chemistry initiative initiated to catalog small molecule metabolites found in Homo sapiens tissues and biofluids, linking chemical structure data with clinical and experimental annotations. It was established through academic leadership at the University of Alberta and designed to support translational research in contexts spanning National Institutes of Health–funded programs, clinical consortia such as Clinical and Translational Science Awards, and international efforts including the Metabolomics Society. The project produced an open-access repository used by researchers in institutions like Harvard University, Stanford University, Massachusetts Institute of Technology, University of Cambridge, and Max Planck Society.

Overview

The project began in 2004 under principal investigators affiliated with the University of Alberta and sought to create a curated database that integrates chemical data, spectroscopic signatures, and physiologic concentrations. Early engagement included partnerships with the Canadian Institutes of Health Research, collaborations with teams at University of Oxford, and alignment with standards promulgated by organizations such as the International Union of Pure and Applied Chemistry and the International Society for Computational Biology. The database has been cited by researchers at Johns Hopkins University, University of California, San Francisco, Yale University, and labs in the European Molecular Biology Laboratory network.

Objectives and Scope

The stated objectives were to compile comprehensive chemical identities for human metabolites, provide concentration ranges across matrices like blood and urine, and enable integration with genomic and proteomic resources maintained by entities such as National Center for Biotechnology Information, European Bioinformatics Institute, and the Wellcome Trust Sanger Institute. The scope encompassed endogenous metabolites, dietary constituents traced by teams at Monash University and Wageningen University, xenobiotics characterized by researchers at FDA laboratories, and microbial metabolites studied by groups at Pasteur Institute and Broad Institute.

Methodology and Data Collection

Methodological frameworks combined analytical chemistry platforms developed in laboratories at University of Toronto, McGill University, ETH Zurich, and University of California, Davis with computational pipelines influenced by standards from World Health Organization initiatives and software tools emerging from the European Bioinformatics Institute. Data collection used mass spectrometry workflows from manufacturers represented in research at Thermo Fisher Scientific and Agilent Technologies, nuclear magnetic resonance techniques advanced by investigators at Bruker Corporation, and chromatographic separations refined in studies at University of British Columbia. Quality control and curation drew on ontologies and metadata practices aligned with projects at Stanford University School of Medicine and the Broad Institute.

Findings and Contributions

The project cataloged thousands of metabolites, provided reference spectra used by consortia at European Molecular Biology Laboratory and Center for Disease Control and Prevention, and enabled biomarker discovery pipelines adopted in translational studies at Mayo Clinic, Cleveland Clinic, Karolinska Institute, and Imperial College London. Contributions include curated concentration ranges employed in clinical metabolomics protocols at Mount Sinai Hospital, reference compound libraries used in drug metabolism research at Pfizer, GlaxoSmithKline, and Novartis, and metabolite annotations supporting systems biology models developed at Santa Fe Institute and Salk Institute for Biological Studies.

Data Access and Tools

Data access mechanisms mirrored open-data initiatives championed by the National Institutes of Health and the Wellcome Trust, offering searchable interfaces and downloadable datasets used by bioinformatics groups at University of Washington and Johns Hopkins University. Tools interoperable with platforms like Galaxy (computational biology project), workflows run in computing centers such as Oak Ridge National Laboratory, and visualization modules inspired by software from EMBL-EBI allowed integration with pathway resources used at European Bioinformatics Institute and databases managed by National Center for Biotechnology Information.

Collaborations and Funding

Funding and collaboration streams involved national agencies such as the Canadian Institutes of Health Research and international funders including the European Commission through collaborative networks involving researchers at University of Tokyo, Seoul National University, Peking University, and University of Melbourne. Academic partnerships extended to clinical centers at Johns Hopkins Hospital, pharmaceutical industry groups at Roche, and standardization efforts with the Metabolomics Society and the International Organization for Standardization.

Criticisms and Limitations

Critiques have focused on completeness and representativeness, echoing concerns raised in meta-analyses from teams at Columbia University, Princeton University, and Duke University about population diversity and matrix coverage. Technical limitations noted by researchers at University of California, San Diego and University College London include sensitivity limits of mass spectrometers from vendors such as Sciex and variable annotation confidence that prompted method harmonization efforts led by Metabolomics Society working groups. Data interoperability challenges involving cross-references to resources at European Bioinformatics Institute and National Center for Biotechnology Information have motivated follow-up projects and standards initiatives supported by the Wellcome Trust and the National Institutes of Health.

Category:Metabolomics